Company Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.
It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
The company is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Dec 11, 1981 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Steven Lo |
Contact Details
Address: 170 Harbor Way South San Francisco, California United States | |
| Website | https://vaxart.com |
Stock Details
| Ticker Symbol | VXRT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000072444 |
| CUSIP Number | 92243A200 |
| ISIN Number | US92243A2006 |
| Employer ID | 59-1212264 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Steven Lo | President, Chief Executive Officer & Director |
| Dr. Raymond D. Stapleton Jr., Ph.D. | Chief Technology Officer |
| Phillip Eric Lee | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Dr. James F. Cummings M.D. | Chief Medical Officer |
| Dr. Rajesh Kapoor Ph.D. | Senior Vice President of Quality |
| Dr. Sean N. Tucker Ph.D. | Senior Vice President & Chief Scientific Officer |
| Edward B. Berg | Senior Vice President & General Counsel |
| Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 31, 2024 | 8-K | Current Report |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 17, 2024 | 4 | Filing |
| Dec 05, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 08, 2024 | 424B5 | Filing |
| Oct 08, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 8-K | Current Report |
| Aug 08, 2024 | 10-Q | Quarterly Report |